Scarica l'app Stockscreener
5.2985
0.58%
-0.0185
Atyr Pharma Inc Borsa (ATYR) Ultime notizie
With 70% ownership, aTyr Pharma, Inc. (NASDAQ:ATYR) boasts of strong institutional backing - Yahoo Finance
Bank of America Corp DE Makes New $330,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - MarketBeat
Cantor Fitzgerald Comments on Atyr PHARMA FY2026 Earnings - MarketBeat
Two Sigma Investments LP Takes Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
91,224 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Bank of America Corp DE - Defense World
Atyr PHARMA (NASDAQ:ATYR) Stock Price Up 6.1%Here's Why - MarketBeat
Cantor Fitzgerald Estimates Atyr PHARMA FY2026 Earnings - Defense World
aTyr: Promising Data But Cash May Be An Issue (NASDAQ:ATYR) - Seeking Alpha
Squarepoint Ops LLC Invests $96,000 in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Two Sigma Advisers LP Makes New $44,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Millennium Management LLC Makes New Investment in Atyr PHARMA INC (NASDAQ:ATYR) - MarketBeat
H.C. Wainwright reaffirms aTyr Pharma stock with a $35 price target - Investing.com UK
Atyr PHARMA (NASDAQ:ATYR) Receives Buy Rating from HC Wainwright - Defense World
aTyr Pharma reports positive interim results for SSc-ILD treatment By Investing.com - Investing.com South Africa
aTyr Pharma Announces Findings from Interim Analysis of - GlobeNewswire
ATYR Stock Update: HC Wainwright Reiterates 'Buy' Rating with $3 - GuruFocus
ATYR Stock Update: HC Wainwright Reiterates 'Buy' Rating with $35 Price Target | ATYR Stock News - GuruFocus
aTyr Pharma reports positive interim results for SSc-ILD treatment - Investing.com Australia
aTyr Pharma (ATYR) Reports Promising Interim Results for Efzofitimod | ATYR Stock News - GuruFocus
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) - GlobeNewswire
Millennium Management LLC Takes $1.33 Million Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Breakthrough: aTyr's New Drug Shows Promising Results in 75% of Severe Scleroderma Patients - Stock Titan
aTyr Pharma (ATYR) Scheduled for Key Presentation in New York | - GuruFocus
aTyr Pharma (ATYR) Scheduled for Key Presentation in New York | ATYR Stock News - GuruFocus
aTyr Pharma stock soars to 52-week high of $4.66 By Investing.com - Investing.com Nigeria
Atyr PHARMA INC (NASDAQ:ATYR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
182,625 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Northern Trust Corp - Defense World
Woodline Partners LP Purchases New Position in Atyr PHARMA INC (NASDAQ:ATYR) - MarketBeat
Atyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
High Growth Tech Stocks in the US to Watch This May 2025 - Yahoo Finance
Group One Trading LLC Takes $26,000 Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Jane Street Group LLC Invests $720,000 in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
aTyr Pharma’s SWOT analysis: biotech firm’s stock poised for potential breakthrough - Investing.com India
aTyr Pharma’s SWOT analysis: biotech firm’s stock poised for potential breakthrough By Investing.com - Investing.com South Africa
aTyr Pharma, Inc. (ATYR): Analysts See 485% Upside Potential - Insider Monkey
aTyr Pharma to Present at Upcoming Investor Conferences - GlobeNewswire
aTyr Pharma Announces Triple Conference Schedule: RBC, Jefferies, and Piper Sandler Healthcare Events Coming Up - Stock Titan
aTyr Pharma (ATYR) Highlights Efzofitimod Research at ATS 2025 | ATYR Stock News - GuruFocus
aTyr Pharma (ATYR) Highlights Efzofitimod Research at ATS 2025 | - GuruFocus
aTyr Pharma (ATYR) Receives Steady 'Buy' Rating from HC Wainwright | ATYR Stock News - GuruFocus
Such Is The Power Of Atyr Pharma Inc (NASDAQ: ATYR) - Stocksregister
aTyr Pharma Presents Three Posters on Efzofitimod at the - GlobeNewswire
Breakthrough Phase 3 Trial Reveals 158,900 Patients Could Benefit from New Sarcoidosis Treatment - Stock Titan
Balyasny Asset Management L.P. Buys Shares of 44,310 Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference - The Manila Times
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rul - GuruFocus
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Dimensional Fund Advisors LP Makes New $881,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
0.34%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):